Literature DB >> 17220402

Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology.

Kim Credito1, Gengrong Lin, Peter C Appelbaum.   

Abstract

The synergistic effects of daptomycin plus gentamicin or rifampin were tested against 50 Staphylococcus aureus strains, with daptomycin MICs ranging between 0.25 and 8 microg/ml. Daptomycin sub-MICs combined with gentamicin concentrations lower than the MIC yielded synergy in 34 (68%) of the 50 strains. Daptomycin combined with rifampin yielded synergy in one vancomycin-intermediate S. aureus strain only, and virtually all synergy occurred between daptomycin and gentamicin.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17220402      PMCID： PMC1855505          DOI： 10.1128/AAC.01455-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  Activities of clinafloxacin, alone and in combination with other compounds, against 45 gram-positive and -negative organisms for which clinafloxacin MICs are high.

Authors:  C L Clark; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

Review 2.  Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey.

Authors:  Stan Deresinski
Journal:  Clin Infect Dis       Date:  2005-01-24       Impact factor: 9.079

3.  Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease?

Authors:  Jovanka M Voyich; Michael Otto; Barun Mathema; Kevin R Braughton; Adeline R Whitney; Diane Welty; R Daniel Long; David W Dorward; Donald J Gardner; Gérard Lina; Barry N Kreiswirth; Frank R DeLeo
Journal:  J Infect Dis       Date:  2006-11-02       Impact factor: 5.226

4.  Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes.

Authors:  John S Francis; Meg C Doherty; Uri Lopatin; Cecilia P Johnston; Gita Sinha; Tracy Ross; Mian Cai; Nadia N Hansel; Trish Perl; John R Ticehurst; Karen Carroll; David L Thomas; Eric Nuermberger; John G Bartlett
Journal:  Clin Infect Dis       Date:  2004-12-07       Impact factor: 9.079

5.  Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections.

Authors:  Benjamin A Lipsky; Uschi Stoutenburgh
Journal:  J Antimicrob Chemother       Date:  2005-01-19       Impact factor: 5.790

6.  Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing.

Authors:  D J Demczar; A N Nafziger; J S Bertino
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

7.  A clone of methicillin-resistant Staphylococcus aureus among professional football players.

Authors:  Sophia V Kazakova; Jeffrey C Hageman; Matthew Matava; Arjun Srinivasan; Larry Phelan; Bernard Garfinkel; Thomas Boo; Sigrid McAllister; Jim Anderson; Bette Jensen; Doug Dodson; David Lonsway; Linda K McDougal; Matthew Arduino; Victoria J Fraser; George Killgore; Fred C Tenover; Sara Cody; Daniel B Jernigan
Journal:  N Engl J Med       Date:  2005-02-03       Impact factor: 91.245

8.  Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.

Authors:  Kerry L LaPlante; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

9.  Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania.

Authors:  Fred C Tenover; Linda M Weigel; Peter C Appelbaum; Linda K McDougal; Jasmine Chaitram; Sigrid McAllister; Nancye Clark; George Killgore; Caroline M O'Hara; Laura Jevitt; Jean B Patel; Bülent Bozdogan
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

10.  Emergence of new strains of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit.

Authors:  C Mary Healy; Kristina G Hulten; Debra L Palazzi; Judith R Campbell; Carol J Baker
Journal:  Clin Infect Dis       Date:  2004-10-27       Impact factor: 9.079
View more
  30 in total

1.  Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.

Authors:  C Garrigós; O Murillo; G Euba; R Verdaguer; F Tubau; C Cabellos; J Cabo; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Subinhibitory concentrations of protein synthesis-inhibiting antibiotics promote increased expression of the agr virulence regulator and production of phenol-soluble modulin cytolysins in community-associated methicillin-resistant Staphylococcus aureus.

Authors:  Hwang-Soo Joo; June L Chan; Gordon Y C Cheung; Michael Otto
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

3.  Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay.

Authors:  Gengrong Lin; Glenn A Pankuch; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2010-02-16       Impact factor: 5.191

4.  Regulation of mprF by antisense RNA restores daptomycin susceptibility to daptomycin-resistant isolates of Staphylococcus aureus.

Authors:  Aileen Rubio; Mary Conrad; Robert J Haselbeck; Kedar G C; Vickie Brown-Driver; John Finn; Jared A Silverman
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

5.  Should daptomycin-rifampin combinations for MSSA/MRSA isolates be avoided because of antagonism?

Authors:  C Stein; O Makarewicz; C Forstner; S Weis; S Hagel; B Löffler; M W Pletz
Journal:  Infection       Date:  2016-01-21       Impact factor: 3.553

6.  Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.

Authors:  Glenn A Pankuch; Gengrong Lin; Harald Seifert; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

7.  Activity of levofloxacin alone and in combination with a DnaK inhibitor against gram-negative rods, including levofloxacin-resistant strains.

Authors:  Kim Credito; Gengrong Lin; Laura Koeth; Michael A Sturgess; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

8.  Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents.

Authors:  Gengrong Lin; Glenn Pankuch; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

9.  Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.

Authors:  Gengrong Lin; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

Review 10.  Daptomycin in bone and joint infections: a review of the literature.

Authors:  Dennis A K Rice; Luke Mendez-Vigo
Journal:  Arch Orthop Trauma Surg       Date:  2008-11-07       Impact factor: 3.067
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.